News coverage about BioTelemetry (NASDAQ:BEAT) has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. BioTelemetry earned a coverage optimism score of 0.23 on Accern’s scale. Accern also assigned news stories about the medical research company an impact score of 46.5315014911198 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Here are some of the media headlines that may have impacted Accern Sentiment’s analysis:

Several analysts recently weighed in on the stock. BidaskClub upgraded shares of BioTelemetry from a “hold” rating to a “buy” rating in a report on Wednesday, February 14th. Zacks Investment Research cut shares of BioTelemetry from a “hold” rating to a “sell” rating in a report on Thursday, February 8th. Raymond James Financial assumed coverage on shares of BioTelemetry in a report on Thursday, October 26th. They issued an “outperform” rating and a $37.00 price target on the stock. Dougherty & Co reiterated a “buy” rating and issued a $40.00 price target on shares of BioTelemetry in a report on Wednesday, November 8th. Finally, SunTrust Banks assumed coverage on shares of BioTelemetry in a report on Monday, October 23rd. They issued a “buy” rating and a $41.00 price target on the stock. Two analysts have rated the stock with a sell rating and seven have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $42.86.

Shares of BioTelemetry (NASDAQ:BEAT) opened at $34.25 on Tuesday. BioTelemetry has a fifty-two week low of $23.30 and a fifty-two week high of $39.20. The company has a market cap of $1,109.98, a price-to-earnings ratio of 26.55, a PEG ratio of 1.52 and a beta of 0.67. The company has a current ratio of 1.60, a quick ratio of 1.48 and a debt-to-equity ratio of 0.75.

ILLEGAL ACTIVITY WARNING: “BioTelemetry (BEAT) Getting Somewhat Positive News Coverage, Analysis Shows” was originally reported by Watch List News and is the property of of Watch List News. If you are reading this piece on another domain, it was illegally stolen and republished in violation of US and international copyright legislation. The original version of this piece can be accessed at

BioTelemetry Company Profile

BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.

Insider Buying and Selling by Quarter for BioTelemetry (NASDAQ:BEAT)

Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with's FREE daily email newsletter.